Associated research groups:

Raab MS, Zamagni E, Manier S, Rodriguez-Otero P, Schjesvold F, Broijl A (2023)
Difficult-to-treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results
EJHaem, 4 (4), 1117-1131
DOI 10.1002/jha2.743, PubMed 38024633

Schjesvold FH, Ludwig H, Mateos MV, Larocca A, Abdulhaq H, Norin S, Thuresson M, Bakker NA, Richardson PG, Sonneveld P (2023)
Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study
Eur J Haematol (in press)
DOI 10.1111/ejh.14127, PubMed 37968873

van de Donk NWCJ, Minnema MC, van der Holt B, Schjesvold F, Wu KL, Broijl A, Roeloffzen WWH, Gadisseur A, Pietrantuono G, Pour L, van der Velden VHJ, Lund T, Offidani M, Grasso M, Giaccone L, Razawy W, Tacchetti P, Mancuso K, Silkjaer T, Caers J, Zweegman S, Hájek R, Benjamin R, Vangsted AJ, Boccadoro M et al. (2023)
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study
Lancet Oncol, 24 (10), 1119-1133
DOI 10.1016/S1470-2045(23)00405-9, PubMed 37717583